ASH2020: Clinical trials have shown that CAR-T cell therapy is highly effective in treating advanced non-Hodgkin's lymphoma

December 7, 2020 /--- Researchers at the Dana-Farber Cancer Institute in the United States reported at the 62nd annual meeting of the American Society of Hematology (ASH) that in a Phase 2 clinical trial, nearly 80 percent of patients with advanced non-Hodgkin's lymphoma (NHL) had reduced levels of cancer cells that could not be detected.
photo source: www.pixabay.com.
that while the NHL is often a slow-growing disease, patients often relapse after standard treatment, highlighting the need for new treatments.
the researchers say the effectiveness of axi-cel in clinical trial participants who have relapsed or developed resistance to other drugs is particularly encouraging.
Caron Jacobson of the Dana-Farber Cancer Institute led the clinical trial.
said, "We were impressed by the magnitude and durability of the treatment response.
treatment has had a meaningful impact on high-risk patients with these diseases.
also realized how safe it was compared to what we saw in the fast-growing lymphoma.
" method of making axi-cel is to collect some disease-resistant T-cells in the patient's body and genetically regenerate them to express a specific subject on the surface.
this gene-modified T-cell ---CAR-T-cell--- can attach to cancer cells and destroy them, according to the study.
then inject these CAR-T cells into the patient.
in previous clinical trials in patients with large B-cell lymphoma, the cell therapy reduced cancer cells below detectable levels and achieved "complete remission" in many patients.
In the current clinical trial, called ZUMA-5, the researchers sent axi-cel to 146 patients with fleatic lymphoma or marginal lymphoma -- two slow-growing non-Hodgkin's leukemia --- at multiple U.S. medical centers.
all participants had active lymphoma despite having received multiple treatments before.
after an average of 17.5 months of axi-cel treatment, 92 percent of clinical trial participants had an objective response---
62% of patients receiving treatment continued to respond by the deadline for data collection.
almost all patients experienced adverse side effects, and 86% experienced adverse events of level 3 or above.
7 percent of patients experienced level 3 or higher cytokine release syndrome and 19 percent experienced level 3 or higher neurological events.
patients with leaching lymphoma had a slightly higher response rate and a slightly lower rate of adverse reactions than those with lymphoma in marginal areas.
Jacobson will announce the findings of this clinical study on Saturday, December 5, at 12:30 p.m. EST in the press release "Advancing New Frontiers: Genome Editing and Cellular Therapy."
further details will be released at Session 623, Abstract 700, on Monday, December 7 at 4:30 p.m. EST.
(Bioon.com) Reference: 1.CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent-Hodgkin Lyman